Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Calaspargase Pegol-mknl + Cytarabine + Idarubicin in Newly Diagnosed AML
NCT04953780Phase 1Active, not recruiting
- Sponsor
- West Virginia University
- Start
- Sep 2021
- Primary completion
- Feb 2030
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of calaspargase pegol in acute myeloid leukemia (AML) (4 arms), sponsored by West Virginia University. Primary endpoint: Regimen Limiting Toxicity at 30 days. Started Sep 2021; status: active, not recruiting.
02
Drugs
calaspargase pegol
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04953780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04953780.